4194.TWO Holy Stone Healthcare Co., Ltd.
- Market cap
- TWD 1.04B
- P/E
- -
- P/B
- 8.67x
- ROE
- -60.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4194.TWO undervalued?
Graham numberThe Graham number of Holy Stone Healthcare Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Holy Stone Healthcare Co., Ltd. fundamental analysis
No fundamental analysis for Holy Stone Healthcare Co., Ltd. yet.
Holy Stone Healthcare Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also de…
Full company profileHoly Stone Healthcare Co., Ltd. financial statements
Holy Stone Healthcare Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 204M | 222M | 217M | 270M | 237M | 119M | 0.00 |
| Gross Profit | 103M | 98.5M | 102M | 123M | 99.4M | 32.9M | 0.00 |
| Operating Income | -187M | -129M | -175M | -149M | -289M | -190M | -146M |
| EBITDA | -173M | -107M | -158M | -128M | -266M | -171M | -98.6M |
| Net Income | -191M | -129M | -181M | -153M | -289M | -183M | -111M |
| EPS | -2.26 | -1.17 | -1.65 | -1.27 | -2.12 | -1.29 | -0.76 |
| Balance Sheet | |||||||
| Total Assets | 656M | 523M | 343M | 615M | 201M | 353M | 221M |
| Total Liabilities | 99.0K | 71.5M | 78.6M | 91.9M | 117M | 58.9M | 37.7M |
| Shareholders' Equity | 576M | 451M | 264M | 523M | 83.4M | 294M | 183M |
| Cash & Short-term Investments | 456M | 351M | 194M | 445M | 85.8M | 267M | 144M |
| Total Debt | 24.5M | 27.0M | 28.8M | 29.1M | 77.0M | 14.4M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -199M | -101M | -138M | -146M | -277M | -143M | -109M |
| Capital Expenditure | 3.26M | 913K | 4.29M | 2.15M | 3.53M | 2.10M | 7.27M |
| Free Cash Flow | -202M | -102M | -142M | -148M | -281M | -145M | -116M |
| Ratios | |||||||
| ROE | -33.1% | -28.5% | -68.7% | -29.3% | -347.1% | -62.4% | -60.9% |
| ROA | -29.1% | -24.6% | -52.9% | -24.9% | -144.3% | -52.0% | -50.5% |
| Net Profit Margin | -93.4% | -58.1% | -83.5% | -56.6% | -122.2% | -154.5% | - |
| Debt to Equity | 0.04x | 0.06x | 0.11x | 0.06x | 0.92x | 0.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Holy Stone Healthcare Co., Ltd. dividends
Holy Stone Healthcare Co., Ltd. has not paid dividends in the last 7 fiscal years.
Last stock split: 886.4:1000 on Jan 25, 2024.
Who owns Holy Stone Healthcare Co., Ltd.
Ownership data of Holy Stone Healthcare Co., Ltd. is not available yet.
Holy Stone Healthcare Co., Ltd. company profile
- Company name
- Holy Stone Healthcare Co., Ltd.
- Ticker
- 4194.TWO
- ISIN
- TW0004194006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 88, Neihu Rd., Taipei, Taiwan, 11493
- Phone
- 886 2 8797 5966
- Website
- hshc.com.tw
About Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer's disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
Holy Stone Healthcare Co., Ltd. management
5- Raymond YangChief Executive Officer
- Bill TangPresident
- Yuling LiuAccounting Supervisor
- Charles HouChief Scientific Officer
- Dr. M. Sherry Ku Ph.D.Chief Scientific Advisor